Patent ID: 8530483

Claim:
A compound represented by Formula I: or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof, wherein: Y is N; A is N, or CH; X is O or S; Z is selected from the group consisting of benzothiazolyl, indolyl, pyrazolopyridinyl, and pyrrolopyridinyl all optionally substituted with 1 to 3 groups of R 2 , R 3 or R 4 , provided that when R 1 is hydrogen or —(CH 2 ) n halo and Z is benzothiazolyl, then the R 2 , R 3 and R 4 substituents on the benzothiazolyl cannot be hydrogen, —(CH 2 ) n halo, —C 1-6 alkyl, —CF 3 , or —(CH 2 ) n OR; R represents hydrogen, or —C 1-6 alkyl; R 1 represents hydrogen, —C 5-10 heterocyclyl, —N(R 2 ) 2 , CN, —(CH 2 ) n halo, CF 3 , —O(CH 2 ) n R, O(CH 2 ) n C 5-10 heterocyclyl, —C 1-6 alkyl, —OCF 3 , —O(CH 2 ) n F, —(O(CH 2 ) s ) p halo, —(O(CH 2 ) s ) p OR, —C(O)OR, or hetero-spirocycle said alkyl, and heterocyclyl optionally substituted with 1 to 3 groups of R a , with the proviso that R 1 , R 2 , R 3 and R 4 are not hydrogen at the same time; R 2 , R 3 and R 4 independently represent hydrogen, —(CH 2 ) n halo, —C 1-6 alkyl, —CF 3 , —(CH 2 ) n OR, (CH 2 ) n C 5-10 heterocyclyl, —N(R) 2 ,said alkyl, and heterocyclyl optionally substituted with 1 to 3 groups of R a ; R a represents —CN, NO 2 , halo, CF 3 , —C 1-6 alkyl, —C 1- 6 alkenyl, —C 1-6 alkynyl, —(CH 2 ) n halo, —OR, —NRR 1 , —C(═NR 1 )NR 2 R 3 , —N(═NR 1 )NR 2 R 3 , —NR l COR 2 , —NR 1 CO 2 R 2 , —NR 1 SO 2 R 4 , —NR 1 CONR 2 R 3, —SR 4 , —SOR 4 , —SO 2 R 4 , —SO 2 NR 1 R 2 , —COR 1 , —CO 2 R 1 , —CONR 1 R 2 , —C(═NR 1 )R 2 ,or —C(═NOR 1 )R 2 ; n represents 0-6; s represents 2-4; and p represents 1-3.